ADVERTISEMENT
3 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Mammoth Biosciences and GSK partner on CRISPR-based COVID-19 test

by Megha Satyanarayana
May 21, 2020 | APPEARED IN VOLUME 98, ISSUE 20

Mammoth Biosciences will partner with GSK Consumer Healthcare to create a handheld, at-home COVID-19 test. The test is based on CRISPR, a gene-editing technology they are deploying to detect viral RNA from SARS-CoV-2, the coronavirus that causes COVID-19. Mammoth says the test will produce results from a nasal swab in under 20 min. The companies expect to apply later this year for a US emergency use authorization.

C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment